Global prevalence of resistance to macrolides in<i>Mycoplasma pneumoniae</i>: a systematic review and meta-analysis

Wang, Guotuan; Wu, Peng; Tang, Rui; Zhang, Weidong

doi:10.1093/jac/dkac170

Cited by 22 publications

(18 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The M. pneumoniae MR rates vary between different geographical regions and change over time. According to a meta‐analysis of studies carried out in 22 countries between 2000 and 2020, among 17 873 M. pneumoniae strains, 8836 (49%) strains were macrolide resistant [39]. The prevalence rate is higher in Asia (63%), and lower in Europe, North America, and other regions of the world (0%–8.6%).…”

Section: Macrolide Resistancementioning

confidence: 99%

Overview of the epidemic characteristics of Mycoplasma pneumoniae infection around COVID pandemic

Sun,

Xiao

2023

iLABMED

View full text Add to dashboard Cite

Mycoplasma pneumoniae (M. pneumoniae) is a cell wall‐less respiratory pathogen causing community‐acquired pneumonia and extrapulmonary manifestations. It is transmitted through close contact and shows periodic regional outbreaks. The coronavirus disease (COVID‐19) pandemic interfered with the global spread of M. pneumoniae. A large‐scale post‐COVID outbreak is currently ongoing in China. To help physicians better understand and manage this epidemic, we provide this review summarizing current knowledge on the pathogenesis, epidemic characteristics, macrolide resistance, diagnostic methods, and clinical treatment strategies for this pathogen.

show abstract

Section: Macrolide Resistancementioning

confidence: 99%

Overview of the epidemic characteristics of Mycoplasma pneumoniae infection around COVID pandemic

Sun,

Xiao

2023

iLABMED

View full text Add to dashboard Cite

show abstract

“…Sin embargo, la mayoría de las veces es necesario el tratamiento antibiótico para mejorar los síntomas clínicos, reducir la duración de la en-sistencia a macrólidos en M. pneumoniae detectó que la resistencia media en Europa es en torno al 3%, obteniendo datos de prevalencia diferentes a lo largo del tiempo. En Europa antes del año 2008 había una prevalencia media de 0.8%, y en el año 2018-2020 la prevalencia media es del 10% [41]. Según la revisión publicada en 2021 por Loncosole et al, la prevalencia más alta en Europa se registra en Italia y Escocia sobre todo a consecuencia de las epidemias que tuvieron en el periodo 2010-2011 [37].…”

Section: Tratamientounclassified

Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?

Varela¹,

Perez²,

Ortega³

et al. 2023

Rev Esp Quimioter

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a bacterium that lacks a cell wall. It produces infections all It produces infections world-wide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique.

show abstract

“…Furthermore, the incidence of macrolide‐resistant MPP is gradually increasing each year 6 . Over the last 20 years, the prevalence of macrolide‐resistant MP in Asia has surpassed 60%, and in China and Korea, it has surpassed 80% 7 . Therefore, there is an urgent need to consider alternative antibiotics for treating MPP.…”

Section: Introductionmentioning

confidence: 99%

“…7 ) copies/mL, p < .05].As shown in Figure3, IL-6 [885.32 (243.94-2388.26) pg/mL versus 143.07 (54.94-317.36) pg/mL], IL-10 [9.94 (5.90-31.99) pg/mL versus 5.16 (1.25-13.12) pg/mL], TNF-α [62.32 (15.91-143.91) pg/mL versus 7.44 (1.25-18.77) pg/mL], and IFN-γ [37.13 (13.43-56.33) pg/ mL versus 5.25 (1.25-18.77) pg/mL] levels of the Fervescence MPP group were significantly increased as compared to those of the Defervescence MPP group (all p < .05). In addition, the inflammatory cell count [4400.00 (2385.00-11630.50) × 10 6 /L versus 2530.00 (1010.00-4860.00) × 10 6 /L], neutrophil count [2097.60 (691.90-8320.93) × 10 6 /L versus 1134.00 (357.35-2460.85) × 10 6 /L), macrophage count [698.00 (377.80-1412.63) × 10 6 /L versus 426.60 (185.40-781.70) × 10 6 /L], and lymphocyte count [855.60 (300.40-1633.70) × 10 6 /L versus 444.60 (136.40-812.40) × 10 6 /L] in the BALF of the Fervescence MPP group increased significantly as compared to those of the Defervescence MPP group (all p < .05).…”

mentioning

confidence: 99%

Analysis of cytokine levels, cytological findings, and MP‐DNA level in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia

Deng

Liang

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background The present study was conducted to determine the inflammatory response in the lungs of children with Mycoplasma pneumoniae pneumonia (MPP). Methods This study retrospectively analyzed cytokine levels, cytological findings, and M. pneumoniae (MP)‐DNA level in the bronchoalveolar lavage fluid (BALF) of 96 children with MPP. The study utilized Spearman's correlation method to evaluate the contribution of BALF and blood parameters in MPP children. Results (1) A total of 96 MPP children were classified into the Low MP‐DNA MPP group (BALF MP‐DNA ≤ 10 5 copies/mL) and the High MP‐DNA MPP group (BALF MP‐DNA > 10 5 copies/mL); the Non‐fever MPP group (no fever during the entire course of pneumonia) and the Fever MPP group; the Defervescence MPP group (fever had subsided at the time of bronchoscopy) and the Fervescence MPP group; and the Mild MPP group and the Severe MPP group. (2) The High MP‐DNA MPP, Fever MPP, Fervescence MPP, and Severe MPP groups had higher levels of interleukin (IL)‐6, IL‐10, and tumor necrosis factor‐α (TNF‐α) in their BALF (all p < .05). (3) The proportions of neutrophils and macrophages in the BALF of the High MP‐DNA MPP and Fever MPP groups increased and decreased, respectively (all p < .05). (4) In the BALF of MPP children, MP‐DNA, IL‐6, IL‐10, TNF‐α, and interferon gamma (IFN‐γ) levels positively correlated with neutrophil proportion while negatively correlated with macrophage proportion (all p < .05). (5) The MP‐DNA, IL‐6, IL‐10, TNF‐α, and IFN‐γ levels in the BALF of MPP children were positively correlated with the levels of C‐reactive protein, procalcitonin, lactic dehydrogenase, fibrinogen, and d‐dimer, while they were negatively correlated with the albumin level (all p < .05). Conclusions In children with MPP, the pulmonary inflammatory immune response was stronger in the High MP‐DNA MPP, Fever MPP, Fervescence MPP, and Severe MPP groups. The relationship between pulmonary cytokine levels, MP‐DNA load, and serum inflammatory parameters were found to be weak.

show abstract

Global prevalence of resistance to macrolides inMycoplasma pneumoniae: a systematic review and meta-analysis

Cited by 22 publications

References 133 publications

Overview of the epidemic characteristics of Mycoplasma pneumoniae infection around COVID pandemic

Overview of the epidemic characteristics of Mycoplasma pneumoniae infection around COVID pandemic

Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?

Analysis of cytokine levels, cytological findings, and MP‐DNA level in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia

Contact Info

Product

Resources

About